Hong Kong stock movement: HAIXI PHARMA fell 11.89%, analysts maintain buy rating but struggle to restore market confidence

Hong Kong Stock Movement HAIXI PHARMA fell by 11.89%. Based on recent key news: On April 25, HAIXI PHARMA's stock price plummeted, despite analysts maintaining a buy rating. Analysts from SWS Res and Shenwan Hongyuan both maintained a buy rating for HAIXI PHARMA, setting a target price of HKD 298.28. However, market confidence in the stock was insufficient, leading to a drop in the stock price to HKD 213.00. On April 24, the market raised doubts about HAIXI PHARMA's future profitability. Although analysts unanimously rated the stock as moderately buy, investors were cautious about its short-term profit outlook, putting pressure on the stock price. On April 23, HAIXI PHARMA's stock price performed poorly, failing to reach analysts' target price. The target price set by analysts was HKD 298.28, while the actual closing price was HKD 237.60, indicating a gap between market expectations and actual performance. The pharmaceutical industry has been volatile recently, and investors should be cautious. Stocks with High Trading Volume in the Industry CSPC Pharmaceutical Group fell by 0.91%. Based on recent news: On April 28, CSPC Pharmaceutical Group announced that its subsidiary CSPC Innovation reported a loss of HKD 93.85 million in the first quarter, widening from a loss of HKD 26.90 million in the same period last year. The loss per share was HKD 0.0674, with a loss of HKD 110 million excluding non-recurring gains and losses, mainly due to the expanded consolidation scope of Giant Biologics, increased shareholding, and increased R&D investment. This news raised concerns among investors about the company's profitability, leading to a decline in the stock price. On April 27, the company's business concentration was relatively high, with approximately 30% of total revenue from neurological drugs and about 8.5% from oncology business in 2025. If sales of core generic drugs decline, there is a lack of sufficient innovative new products to offset the performance gap. CSPC has attempted forecast-based business development in recent years, which, while temporarily boosting market value, has also consumed market trust. If it cannot sustain more significant business development projects or if pipeline R&D progress falls short of expectations, its performance could easily stall again. This news further exacerbated market concerns about the company's future development, putting pressure on the stock price. On April 27, the ORR of SYS6010 (EGFR-ADC) in Phase II clinical trials was only 39.2%, lower than competing products, with an incidence of grade ≥3 adverse reactions reaching 49.8%, raising doubts about its commercialization prospects. This news led investors to question the market prospects of the company's innovative drugs, affecting stock performance. The industry has high concentration, and the prospects for innovative drugs are uncertain. China Biologic Products fell by 0.72%. Based on recent key news: On April 27, China Biologic Products spent HKD 10.0473 million to repurchase 1.81 million shares. This move demonstrates the company's confidence in its own stock; however, the market reaction was not as expected, and the stock price still fell. There have been no other significant news recently. The Hong Kong market has been volatile recently, and investors should be cautious Kailaiying rose by 7.62%. Based on recent key news: On April 27, Kailaiying released its Q1 2026 performance report, with operating revenue increasing by 16.91% year-on-year, but net profit decreasing by 6.82%, mainly due to high exchange losses caused by the appreciation of the RMB. This news attracted market attention and drove the stock price up. On April 27, Goldman Sachs released a research report maintaining a "Buy" rating on Kailaiying, believing that its performance in the CDMO industry is stable and that there is good visibility for future projects. This rating boosted market confidence and propelled the stock price upward. On April 28, Kailaiying announced that emerging business revenue grew by 74.07%, with strong growth in the chemical macromolecule and biological macromolecule business segments, further enhancing investors' expectations for the company's future growth. The overall recovery of the pharmaceutical industry and the weakening of policy impacts. Stocks ranked among the top in industry market capitalization Hengrui Medicine rose by 1.11%. Based on recent key news: On April 27, Hengrui Medicine collaborated with Kailera to develop a GLP-1 product portfolio, expecting to enjoy global value-added benefits from innovative assets in the next 3-5 years, driving the stock price up. Zhitong Finance On April 27, CMB International raised Hengrui Medicine's target price to HKD 74, with Q1 performance exceeding expectations and innovative drug sales revenue increasing by 26% year-on-year, boosting market confidence. Zhitong Finance On April 27, Hengrui Medicine's Q1 revenue grew by 13%, with non-oncology product sales revenue increasing by 92% year-on-year, indicating successful innovation transformation, benefiting the stock price. Zhitong Finance The Hong Kong stock pharmaceutical sector is fluctuating, with weak liquidity